full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
https://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for the ‘blog’ Category

08
Jul

AstraZeneca and Ironwood Pharmaceuticals say their Phase III study for linaclotide, conducted primarily in China among patients with irritable bowel syndrome with constipation, came through on all primary and secondary endpoints. …read more Source: AstraZeneca, Ironwood score PhIII success in China     

08
Jul

Back in February, Afferent Pharmaceuticals pronounced itself satisfied with the outcome for a mid-stage study of its lead drug, AF-219, being developed for a range of conditions including pain, persistent coughing and urinary urgency. And today the venture backers behind the San Mateo-based biotech have come up with $55 million in a crossover round to […]

08
Jul

Parisian drug developer Gensight Biologics is swinging for a $100 million U.S. IPO to fund its work on potential one-time treatments for serious retinal diseases, angling to take advantage of a bullish market for biotechs. …read more Source: Gensight scouts a $100M IPO for its ocular gene therapies     

07
Jul

Essex Woodlands is making progress with its ninth life sciences fund. The group noted in an SEC filing that it has raised $360 million of a planned $750 million fund, up from the $221 million it had raised and then reported last year. …read more Source: Essex Woodlands raises $360M for new life sciences fund […]

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off